After India and China completed their disengagement process in one part of border territory in Leh Ladakh, US State Department spokesperson Ned Price said that the United States welcomes the ongoing efforts to deescalate the situation and will continue to monitor the situation closely as both sides work toward a peaceful resolution.
At a press briefing, Price said, "We are closely following reports of troop disengagement and we welcome the ongoing efforts to deescalate the situation. We will continue to monitor the situation closely as both sides work toward a peaceful resolution."
When asked about India and US coordination on COVID-19 vaccines, Price said, "India and US build on decades of successful partnership and health and by the medical research, we are partnering to strengthen the global response to COVID-19."
"US and India recently welcomed an initiative to collaborate through an international center of excellence in research focused on infectious disease including Covid and we look forward to an overarching memorandum of understanding (MoU) to enhance health cooperation," he said.
Price further said that US and India are working together on developing diagnostics therapeutics vaccines to combat the disease and to recognise the importance of manufacturing critical drugs during this time and making them accessible globally.
"India's pharmaceutical sector is strong and well-established and has long played a central role in manufacturing life-saving vaccines for global use. We are pleased that the US pharmaceutical industry has been coordinating with the Indian pharma industry since the beginning of the COVID-19 pandemic," he added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)